Side-by-side · Research reference
GLP-1 (7-37)vsMT-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED16/43 cited
BFDA-ApprovedHUMAN-REVIEWED9/51 cited
GLP-1 (7-37)
Incretin Hormone · Native Peptide
Research use only · IV/SC in experimental settings
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
01Mechanism of Action
Parameter
GLP-1 (7-37)
MT-1
Primary target
GLP-1 receptor (class B GPCR)Koole 2015
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Pathway
GLP-1R activation → cAMP production → PKA signaling → insulin secretion (pancreatic β-cells)Lu 2025Koole 2015
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Downstream effect
Glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, reduced food intakeLu 2025Ding 2017
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Feedback intact?
Yes — physiological secretion and degradation preserved
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Origin
Endogenous peptide cleaved from proglucagon in intestinal L cells; secreted postprandially
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Antibody development
—
—
02Dosage Protocols
Parameter
GLP-1 (7-37)
MT-1
Clinical use
None — native GLP-1 not used therapeutically
Engineered analogues (semaglutide, liraglutide) used clinically.Friedman 2024
—
Research dosing
Variable — 0.1–10 nmol/kg in animal models
Used as reference standard for analogue comparison.
—
Modified analogues
t½ extended to 13 h (liraglutide), 165 h (semaglutide)
Via DPP-4 resistance + fatty acid acylation.
—
Standard dose
—
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
Frequency
—
Every 60 days
Sustained release implant — no daily administration required.
Evidence basis
—
Phase 3 RCT / FDA-approved orphan drug
Indication
—
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
Duration
—
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
Route
—
Subcutaneous implant — upper arm or abdomen
Stability
—
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
03Metabolic / Fat Loss Evidence
Parameter
GLP-1 (7-37)
MT-1
Mechanism
GLP-1R activation in hypothalamic satiety centers (arcuate nucleus) reduces food intakeLu 2025
Effect demonstrated with long-acting analogues (liraglutide).Lu 2025
—
Native GLP-1 efficacy
Minimal — rapid degradation prevents sustained appetite suppression
—
Gastric emptying
Delayed in animal models, contributing to satiety
—
Body weight impact
Not observed with native GLP-1 — requires analogue formulations
—
04Side Effects & Safety
Parameter
GLP-1 (7-37)
MT-1
Native GLP-1
Well-tolerated in research settings; no prolonged exposure data
—
Hypoglycemia risk
Low — insulin secretion is glucose-dependent
—
Analogue side effects
Nausea, vomiting, diarrhea (GLP-1R agonists)
Not applicable to native GLP-1 due to non-therapeutic use.
—
GLP-1 resistance
High glucose-induced PKCβ overexpression may reduce GLP-1 responsiveness in endothelial cellsPujadas 2016
—
Nausea
—
Common (>10%) — mild, transient
Implant site reaction
—
Erythema, bruising, tenderness at insertion site
Hyperpigmentation
—
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
Melanocytic changes
—
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
Headache
—
Occasional (MC1R-independent melanocortin effects)
Photosensitivity (paradoxical)
—
Rare phototoxic reactions despite melanin increase
Contamination risk (unregulated)
—
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
Absolute Contraindications
GLP-1 (7-37)
—MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Relative Contraindications
GLP-1 (7-37)
—MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
05Administration Protocol
Parameter
GLP-1 (7-37)
MT-1
1. Research use only
Native GLP-1(7-37) is not formulated for therapeutic use. Administered IV or SC in experimental protocols to study GLP-1R pharmacology and as reference standard for analogue development.
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
2. Storage
Lyophilised peptide stored at -20°C or below. Reconstituted solutions should be prepared fresh and used immediately due to rapid degradation.
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
3. Clinical alternatives
For therapeutic GLP-1R activation, use FDA-approved long-acting analogues: semaglutide (once weekly), liraglutide (once daily), dulaglutide (once weekly), or exenatide (twice daily or once weekly).
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
4. Repeat dosing
—
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
5. Monitoring
—
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.